EICHORPublic-registry site landscape for NCT03262610, “Setmelanotide in a Single Patient With Partial Lipodystrophy”, a Hypertriglyceridemia study sponsored by Rhythm Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03262610 (registry record) |
| Study title | Setmelanotide in a Single Patient With Partial Lipodystrophy |
| Official title | Expanded-access for the Use of Setmelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases |
| Sponsor | Rhythm Pharmaceuticals, Inc. |
| Condition(s) | Hypertriglyceridemia; Obesity |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03262610.
Eichor generates a preliminary site-risk snapshot for NCT03262610 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Hypertriglyceridemia trials
← Eichor home · All tracked trials · Hypertriglyceridemia studies · Weekly briefs
